This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| EZH2 | |
|---|---|
| Name | EZH2 |
| Uniprot | Q15910 |
| Organism | Homo sapiens |
| Length | 741 |
EZH2 is a histone-modifying enzyme that functions as a catalytic subunit within a polycomb repressive complex involved in transcriptional repression. It plays critical roles in chromatin organization, cellular differentiation, and proliferation across multiple tissues and developmental stages. Mutations, amplification, or dysregulation of the protein have been linked to several cancers and developmental syndromes.
The protein comprises a SET domain responsible for lysine methyltransferase activity and a CXC zinc-finger-like motif; crystal structures resolved by groups associated with European Molecular Biology Laboratory and University of California, San Diego clarified substrate recognition and S-adenosylmethionine coordination. High-resolution studies used techniques from X-ray crystallography and Cryo-EM performed at facilities such as the Diamond Light Source and National Institutes of Health centers. Primary sequence analysis referenced databases like UniProt and structural classifications from the Protein Data Bank to map conserved residues and post-translational modification sites identified by mass spectrometry groups at Cold Spring Harbor Laboratory and Max Planck Institute.
EZH2's catalytic activity transfers methyl groups to histone H3 lysine 27 (H3K27), establishing mono-, di-, and tri-methyl marks that are recognized by readers within complexes studied at Broad Institute and Stanford University. The methylation state influences recruitment of chromatin remodelers characterized in work at Harvard Medical School and Massachusetts Institute of Technology. Functional assays performed using chromatin immunoprecipitation by teams at EMBL-EBI and genome-wide profiling using platforms from Illumina and Affymetrix linked EZH2-dependent marks to repression of loci regulated during programs described in studies at University of Cambridge and Johns Hopkins University.
Regulatory control involves phosphorylation by kinases such as those studied at Salk Institute for Biological Studies and Cold Spring Harbor Laboratory, ubiquitination by ligases reported from Dana-Farber Cancer Institute and interactions with accessory proteins identified in proteomics screens at Max Delbrück Center, Karolinska Institutet, and Wellcome Trust Sanger Institute. EZH2 assembles within multi-protein assemblies alongside components mapped by researchers at Institut Curie and National Cancer Institute, where interactions with chromatin-binding factors elucidated by groups at Yale University and University of Oxford modulate complex stability and genomic targeting.
Genetic and developmental biology studies at institutions including University of Chicago and University of Pennsylvania linked EZH2 activity to lineage specification in contexts such as hematopoiesis examined at Fred Hutchinson Cancer Center and neurodevelopment investigated at University College London and Karolinska Institutet. Models using organisms maintained by laboratories at The Jackson Laboratory and European Molecular Biology Laboratory revealed roles in stem cell pluripotency described in reports from Broad Institute and epigenetic reprogramming analyzed at Salk Institute for Biological Studies and Cold Spring Harbor Laboratory. Cell cycle control studies connecting EZH2 to proliferation were carried out at Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.
Somatic mutations, copy-number alterations, and overexpression have been documented in malignancies profiled by consortia such as The Cancer Genome Atlas and International Cancer Genome Consortium; notable associations include lymphomas cataloged by National Cancer Institute investigators and solid tumors reported by teams at Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. Germline variants linked to developmental disorders were described in clinical genetics reports from Mayo Clinic and Great Ormond Street Hospital. Functional genomics studies at Broad Institute and translational research at University of Texas MD Anderson Cancer Center connected altered methylation landscapes to oncogenic transcriptional programs mapped using platforms by Illumina and computational analyses from European Bioinformatics Institute.
Small-molecule inhibitors developed by pharmaceutical groups at GlaxoSmithKline, Epizyme, and academic collaborations with Harvard Medical School and Novartis target the SET domain and allosteric sites characterized in preclinical studies at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. Clinical trials registered with oversight from U.S. Food and Drug Administration and coordinated through centers including Mayo Clinic and Massachusetts General Hospital have evaluated agents in hematologic malignancies and solid tumors; combination strategies with agents investigated at University of California, San Francisco and MD Anderson Cancer Center explore synergy with DNA-damaging drugs and immune modulators studied at National Institutes of Health. Resistance mechanisms monitored in studies from Broad Institute and Wellcome Trust Sanger Institute guide next-generation inhibitor design pursued by teams at Genentech and AstraZeneca.